3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Fátima Cardoso; Eric P. Winer; Giuseppe Curigliano; Fedro A. Peccatori; Binghe Xu; D. Corneliussen-James; A. Costa; Jean‐Yves Pierga; Daniel Vorobiof; Lillie D. Shockney; Efthymios Papadopoulos; Prudence A. Francis; Nadia Harbeck; Ian E. Krop; Matti Aapro; Maria João Cardoso; Larry Norton; Alessandra Gennari; Clifford A. Hudis; Bella Kaufman; Laura Biganzoli; Véronique Dièras; Shinji Ohno; Elżbieta Senkus; Hanneke Meijer; Alexandru Eniu; Frédérique Penault‐Llorca; George W. Sledge; Sandra M. Swain; Karen A. Gelmon; Olivia Pagani; Jonas Bergh; Shirley Mertz; Lesley Fallowfield; Andrew Tutt; Martine Piccart; Hope S. Rugo; Musa Mayer; Carlos H. Barrios; N. El Saghir; G.S. Bhattacharyya; D. Fenech; Christoph Thomssen; L. Carey; Fabrice André

doi:10.1093/annonc/mdw544

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Fátima Cardoso(Breast Cancer Alliance), Eric P. Winer(University of Vermont), Giuseppe Curigliano(European Institute of Oncology), Fedro A. Peccatori(European Institute of Oncology), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), D. Corneliussen-James(METAvivor), A. Costa(European School of Oncology), Jean‐Yves Pierga(Université Paris Cité), Daniel Vorobiof(The Medical Oncology Centre of Rosebank), Lillie D. Shockney(Breast Center), Efthymios Papadopoulos(Louisiana State University), Prudence A. Francis(Peter MacCallum Cancer Centre), Nadia Harbeck(Breast Center), Ian E. Krop(Yale Cancer Center), Matti Aapro(Clinique de Genolier), Maria João Cardoso(Champalimaud Foundation), Larry Norton(Memorial Sloan Kettering Cancer Center), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Clifford A. Hudis(American Society of Clinical Oncology), Bella Kaufman(NYU Langone Health), Laura Biganzoli(Hospital of Prato), Véronique Dièras(Institut Curie), Shinji Ohno(Unknown), Elżbieta Senkus(Gdańsk Medical University), Hanneke Meijer(Radboud University Nijmegen), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Frédérique Penault‐Llorca(Inserm), George W. Sledge(Caris Life Sciences (United States)), Sandra M. Swain(Georgetown University), Karen A. Gelmon(University of British Columbia), Olivia Pagani(Swiss Group For Clinical Cancer Research), Jonas Bergh(Karolinska Institutet), Shirley Mertz(Metastatic Breast Cancer Network), Lesley Fallowfield(Brighton and Sussex Medical School), Andrew Tutt(Institute of Cancer Research), Martine Piccart(Université Libre de Bruxelles), Hope S. Rugo(City of Hope), Musa Mayer, Carlos H. Barrios(Eastern Cooperative Oncology Group), N. El Saghir(American University of Beirut), G.S. Bhattacharyya(Fortis Hospital), D. Fenech, Christoph Thomssen(Martin Luther University Halle-Wittenberg), L. Carey(UNC Lineberger Comprehensive Cancer Center), Fabrice André(Inserm)

Annals of Oncology

October 11, 2016

10.1093/annonc/mdw544

Cited by 2,062

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

|The Lancet|2016|4.8k

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

|The Lancet|2014|4.7k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.3k

Pembrolizumab for Early Triple-Negative Breast Cancer

|New England Journal of Medicine|2020|3.1k

Palbociclib and Letrozole in Advanced Breast Cancer

|New England Journal of Medicine|2016|2.9k